Avoiding Commercialization Pitfalls for CGTs

Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices.

In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT,Cencora(formerly AmerisourceBergen), discusses:

• Defining CGT commercialization strategies and foundational knowledge—and the best music metaphor
• What he wishes companies knew about commercialization strategies
• Common knowledge gaps of CGTs
• How CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access
• How planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies
• How companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies)
• When to start planning a CGT commercialization strategy
• Predictions for the CGT market in five years

About the speaker

Lung-I Cheng, PhD, is a vice president and head of Cencora’s CGT service line. He is responsible for advancing Cencora’s CGT strategy with a focus on expanding the company’s portfolio of services to better support CGT innovators throughout the product development and commercialization journey. Prior to joining Cencora(formerly AmerisourceBergen) in May 2022, he spent a decade in biopharma—most recently serving as the head of global value and access for cell therapies, pipeline, and business development at Takeda.

About the Pharm Exec Podcast

The editors of Pharmaceutical Executive bring you the latest commercial insights to master the science of success. Podcast episodes examine current trends, key conferences, and critical topics in the bio/pharmaceutical industry.

Listen to this podcast on SoundCloud, Spotify, Google Podcasts, or Apple Podcasts.